Articles by Anna Rose Welch

  1. FDA News Roundup: Bristol-Myers Squibb, Bayer, Astellas, And More 3/11/2015

    What FDA decisions have you missed in the last week?

  2. FDA News Roundup: Shire, Bristol-Myers Squibb, Alexion, And More 3/6/2015

    What FDA decisions did you miss this week?

  3. Will 2015 Be The Year Of Drug Pricing Transparency? 3/6/2015

    Lately, the pharma industry has been facing a large amount of resistance to its own price tags. In the past year, we’ve been greeted by headlines about drugs launching with $90-, $100-, and even $140,000-per-patient treatment regimens.  But we’ve also been greeted with reports about the high cost of development—a $2.6 billion endeavor, Tufts Center for the Study of Drug Development reported last fall.

  4. FDA News Roundup: Pfizer, Novartis, Sanofi, and More 3/2/2015

    What drug approvals have you missed recently?

  5. How To Snag A Drug R&D Partner: 3 Takeaways From Merck's Latest Deal 2/27/2015

    It’s been a week of high-profile acquisitions. We saw Bristol-Myers Squibb snap up Flexus Biosciences for its immunotherapy programs. Shire bought Meritage Pharma. After the Allergan flop, Valeant finally got Salix Pharma to go steady, and Ipsen shelled out 6 million euros to buy U.K.-based biotech Canbex. But arguably more attention was placed on one $450 million collaboration than on the billions spent in this latest batch of acquisitions.

  6. Poll Expected Sanofi CEO To Be Male: What's Up With That? 2/20/2015

    I’m interested in the topic of gender in any industry, and this week, a headline in BioSpace caught my eye: “Poll Finds Massive Support for French, Male CEO at Sanofi.” According to this survey, 86 percent of responders (353 people) believed the new CEO would be male. Turns out, these responders were right: Soon-to-be-former Bayer CEO, Olivier Brandicourt, will be taking over as Sanofi CEO on April 2.

  7. 2015 Blockbusters: What Drugs Will Show Pharma The Money? 2/13/2015

    Last February, there were four drugs pegged by The Motley Fool as potential blockbusters for 2014. Now, The Motley Fool has released two new lists: its contenders for 2015 blockbusters, and a list of those blockbusters that are on their way out as quickly as the video store packed up and left town. Which drugs are expected to be the winners this year?

  8. FDA's "Compassionate Use" Gets Simpler: What Will This Mean For Drug Manufacturers? 2/6/2015

    Since the beginning of the year, there have been a number of stories crossing my desk focusing on patients’ “Right to Try” experimental drugs.  But I’m also curious what this will mean for drug manufacturers who will no doubt be faced with more of these requests in the future.

  9. What “Unboiling” An Egg Can Mean For Cancer Drug Development 1/28/2015

    In a strange and exciting twist, researchers from the University of California, Irvine (UCI) and Flinders University announced this week they have discovered a new way to “unboil” a hen’s egg — a task that could have huge ramifications for the biotech industry as it races to get cancer meds to patients faster.

  10. What Could Senator Warren's “Swear Jar” Bill Mean For Pharma's Image? 1/28/2015

    President Obama’s recent State of the Union speech addressing precision medicine wasn’t the only government initiative to hit headlines recently. Massachusetts’ senator, Elizabeth Warren, recently proposed what she has dubbed the "swear jar" bill, aka the Medical Innovation Act, which would require big, law-breaking drug makers to send 1 percent of each blockbuster’s annual profits to the NIH for research.